<DOC>
	<DOCNO>NCT02456558</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiretroviral activity , pharmacokinetics , pharmacodynamics intravenous formulation deferiprone HIV-infected subject .</brief_summary>
	<brief_title>Evaluation Safety , Efficacy , Pharmacokinetics Intravenous Deferiprone HIV-Positive Subjects</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomized trial 30 asymptomatic HIV-positive adult . There two sequential cohort , subject receive either one 2 dos deferiprone placebo twice daily .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>HIV1 positive HIV treatmentnaïve : previous treatment combination antiretroviral therapy ( cART ) highly active antiretroviral therapy ( HAART ) regimen HIV1 RNA &gt; 10,000 copies/mL ALT AST ≤ 2.0 x upper limit normal range , bilirubin within normal range Body mass index ( BMI ) 18.5 30.0 kg/m^2 Absolute neutrophil count baseline ≥1.0 x 10^9/L ( black African population ) ≥1.5 x 10^9/L ( race ) Evidence AIDSassociated illness , exclude superficial candidiasis CD4+ Tcell count &lt; 350/mm^3 Positive active latent tuberculosis , determine QuantiFERON®TB Gold test Active , serious infection ( HIV1 infection ) within 30 day prior screen Positive hepatitis B surface antigen ( HBsAg ) and/or hepatitis virus C ( HCV ) antibodies History presence malignancy A serious , unstable chronic illness past 3 month screen A serious , unresolved acute illness screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>antiretroviral drug</keyword>
	<keyword>deferiprone</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>